Does the media favor EDIT or BEAM?

In the previous week, Beam Therapeutics had 2 more articles in the media than Editas Medicine. MarketBeat recorded 3 mentions for Beam Therapeutics and 1 mentions for Editas Medicine. Beam Therapeutics' average media sentiment score of 1.20 beat Editas Medicine's score of 1.16 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CRSP or EDIT?

In the previous week, CRISPR Therapeutics had 8 more articles in the media than Editas Medicine. MarketBeat recorded 9 mentions for CRISPR Therapeutics and 1 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 1.16 beat CRISPR Therapeutics' score of 0.71 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NTLA or EDIT?

In the previous week, Intellia Therapeutics had 2 more articles in the media than Editas Medicine. MarketBeat recorded 3 mentions for Intellia Therapeutics and 1 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 1.16 beat Intellia Therapeutics' score of 0.89 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IMTX or EDIT more profitable?

Editas Medicine has a net margin of -281.59% compared to Immatics' net margin of -572.35%. Immatics' return on equity of -47.36% beat Editas Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Immatics -572.35% -47.36% -39.35% Editas Medicine -281.59% -677.39% -58.25%

Does the media prefer IMTX or EDIT?

In the previous week, Immatics had 1 more articles in the media than Editas Medicine. MarketBeat recorded 2 mentions for Immatics and 1 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 1.16 beat Immatics' score of 0.93 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immatics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CRVS or EDIT?

In the previous week, Corvus Pharmaceuticals had 4 more articles in the media than Editas Medicine. MarketBeat recorded 5 mentions for Corvus Pharmaceuticals and 1 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 1.16 beat Corvus Pharmaceuticals' score of 1.07 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Editas Medicine (EDIT) Competitors

$2.88 -0.10 (-3.36%)

Closing price 04:00 PM Eastern

Extended Trading

$2.87 -0.01 (-0.28%)

As of 04:56 PM Eastern

Compare

EDIT vs. BEAM, CRSP, NTLA, IMTX, and CRVS

Should you buy Editas Medicine stock or one of its competitors? MarketBeat compares Editas Medicine with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Editas Medicine include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Immatics (IMTX), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "pharmaceutical products" industry.

How does Editas Medicine compare to Beam Therapeutics?

Editas Medicine (NASDAQ:EDIT) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

Beam Therapeutics has a net margin of -39.66% compared to Editas Medicine's net margin of -281.59%. Beam Therapeutics' return on equity of -29.00% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

Editas Medicine currently has a consensus price target of $5.40, suggesting a potential upside of 87.50%. Beam Therapeutics has a consensus price target of $46.85, suggesting a potential upside of 77.92%. Given Editas Medicine's higher possible upside, equities analysts clearly believe Editas Medicine is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 3.1% of Editas Medicine shares are owned by insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Beam Therapeutics has higher revenue and earnings than Editas Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	6.96	-$160.06M	-$1.23	N/A
Beam Therapeutics	$139.74M	19.38	-$79.99M	-$0.68	N/A

In the previous week, Beam Therapeutics had 2 more articles in the media than Editas Medicine. MarketBeat recorded 3 mentions for Beam Therapeutics and 1 mentions for Editas Medicine. Beam Therapeutics' average media sentiment score of 1.20 beat Editas Medicine's score of 1.16 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Editas Medicine has a beta of 2.1, indicating that its share price is 110% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the broader market.

Summary

Beam Therapeutics beats Editas Medicine on 15 of the 17 factors compared between the two stocks.

How does Editas Medicine compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Editas Medicine (NASDAQ:EDIT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

Editas Medicine has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,291.22	-$581.60M	-$6.22	N/A
Editas Medicine	$40.52M	6.96	-$160.06M	-$1.23	N/A

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 4.3% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 3.1% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

CRISPR Therapeutics presently has a consensus price target of $67.78, suggesting a potential upside of 44.24%. Editas Medicine has a consensus price target of $5.40, suggesting a potential upside of 87.50%. Given Editas Medicine's higher probable upside, analysts plainly believe Editas Medicine is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, CRISPR Therapeutics had 8 more articles in the media than Editas Medicine. MarketBeat recorded 9 mentions for CRISPR Therapeutics and 1 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 1.16 beat CRISPR Therapeutics' score of 0.71 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Editas Medicine has a net margin of -281.59% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Editas Medicine	-281.59%	-677.39%	-58.25%

CRISPR Therapeutics has a beta of 1.71, meaning that its stock price is 71% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.1, meaning that its stock price is 110% more volatile than the broader market.

Summary

Editas Medicine beats CRISPR Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Editas Medicine compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 3.5% of Intellia Therapeutics shares are held by company insiders. Comparatively, 3.1% of Editas Medicine shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Intellia Therapeutics presently has a consensus price target of $20.19, suggesting a potential upside of 84.87%. Editas Medicine has a consensus price target of $5.40, suggesting a potential upside of 87.50%. Given Editas Medicine's stronger consensus rating and higher probable upside, analysts clearly believe Editas Medicine is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	4 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.30
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Editas Medicine has lower revenue, but higher earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	22.55	-$412.69M	-$3.54	N/A
Editas Medicine	$40.52M	6.96	-$160.06M	-$1.23	N/A

In the previous week, Intellia Therapeutics had 2 more articles in the media than Editas Medicine. MarketBeat recorded 3 mentions for Intellia Therapeutics and 1 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 1.16 beat Intellia Therapeutics' score of 0.89 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Editas Medicine has a net margin of -281.59% compared to Intellia Therapeutics' net margin of -597.04%. Intellia Therapeutics' return on equity of -57.47% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-597.04%	-57.47%	-46.24%
Editas Medicine	-281.59%	-677.39%	-58.25%

Intellia Therapeutics has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.1, indicating that its stock price is 110% more volatile than the broader market.

Summary

Intellia Therapeutics beats Editas Medicine on 9 of the 17 factors compared between the two stocks.

How does Editas Medicine compare to Immatics?

Immatics (NASDAQ:IMTX) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

Immatics has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.1, meaning that its share price is 110% more volatile than the broader market.

In the previous week, Immatics had 1 more articles in the media than Editas Medicine. MarketBeat recorded 2 mentions for Immatics and 1 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 1.16 beat Immatics' score of 0.93 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immatics presently has a consensus target price of $20.80, indicating a potential upside of 125.35%. Editas Medicine has a consensus target price of $5.40, indicating a potential upside of 87.50%. Given Immatics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Immatics is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

64.4% of Immatics shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 3.3% of Immatics shares are owned by company insiders. Comparatively, 3.1% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Editas Medicine has a net margin of -281.59% compared to Immatics' net margin of -572.35%. Immatics' return on equity of -47.36% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-572.35%	-47.36%	-39.35%
Editas Medicine	-281.59%	-677.39%	-58.25%

Editas Medicine has lower revenue, but higher earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$54.60M	22.66	-$222.26M	-$1.99	N/A
Editas Medicine	$40.52M	6.96	-$160.06M	-$1.23	N/A

Summary

Immatics beats Editas Medicine on 9 of the 16 factors compared between the two stocks.

How does Editas Medicine compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 19.7% of Corvus Pharmaceuticals shares are held by company insiders. Comparatively, 3.1% of Editas Medicine shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Corvus Pharmaceuticals has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.1, indicating that its share price is 110% more volatile than the broader market.

Corvus Pharmaceuticals has a net margin of 0.00% compared to Editas Medicine's net margin of -281.59%. Corvus Pharmaceuticals' return on equity of -38.92% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%
Editas Medicine	-281.59%	-677.39%	-58.25%

Corvus Pharmaceuticals has higher earnings, but lower revenue than Editas Medicine. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A
Editas Medicine	$40.52M	6.96	-$160.06M	-$1.23	N/A

Corvus Pharmaceuticals presently has a consensus price target of $33.33, suggesting a potential upside of 136.41%. Editas Medicine has a consensus price target of $5.40, suggesting a potential upside of 87.50%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Corvus Pharmaceuticals is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Corvus Pharmaceuticals had 4 more articles in the media than Editas Medicine. MarketBeat recorded 5 mentions for Corvus Pharmaceuticals and 1 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 1.16 beat Corvus Pharmaceuticals' score of 1.07 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Corvus Pharmaceuticals beats Editas Medicine on 10 of the 15 factors compared between the two stocks.

Get Editas Medicine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EDIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EDIT vs. The Competition

Export

Metric	Editas Medicine	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$281.98M	$3.63B	$6.78B	$12.28B
Dividend Yield	N/A	2.17%	2.67%	9.36%
P/E Ratio	-2.34	20.69	27.12	23.98
Price / Sales	6.96	301.68	572.82	112.50
Price / Cash	N/A	60.31	29.05	48.09
Price / Book	10.29	7.92	10.65	6.14
Net Income	-$160.06M	$23.81M	$3.59B	$331.63M
7 Day Performance	-8.86%	-1.68%	-1.61%	-1.68%
1 Month Performance	7.06%	2.17%	1.01%	-1.40%
1 Year Performance	4.35%	42.55%	23.83%	17.10%

Editas Medicine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EDIT Editas Medicine	2.8307 of 5 stars	$2.88 -3.4%	$5.40 +87.5%	+8.0%	$281.98M	$40.52M	N/A	230	Positive News Analyst Forecast
BEAM Beam Therapeutics	3.5081 of 5 stars	$30.89 -0.4%	$46.85 +51.7%	+32.7%	$3.19B	$139.74M	N/A	510	Positive News Analyst Forecast
CRSP CRISPR Therapeutics	3.4147 of 5 stars	$50.46 -0.3%	$67.78 +34.3%	-26.6%	$4.88B	$3.51M	N/A	460	Analyst Forecast
NTLA Intellia Therapeutics	3.303 of 5 stars	$13.30 +2.2%	$20.67 +55.4%	-5.6%	$1.82B	$67.67M	N/A	600	Gap Down
IMTX Immatics	2.4701 of 5 stars	$9.35 +1.3%	$20.80 +122.5%	+59.8%	$1.24B	$54.60M	N/A	260	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EDIT) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Editas Medicine (EDIT) Competitors

EDIT vs. BEAM, CRSP, NTLA, IMTX, and CRVS

How does Editas Medicine compare to Beam Therapeutics?

Summary

How does Editas Medicine compare to CRISPR Therapeutics?

Summary

How does Editas Medicine compare to Intellia Therapeutics?

Summary

How does Editas Medicine compare to Immatics?

Summary

How does Editas Medicine compare to Corvus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDIT vs. The Competition

Editas Medicine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Editas Medicine (EDIT) Competitors

EDIT vs. BEAM, CRSP, NTLA, IMTX, and CRVS

How does Editas Medicine compare to Beam Therapeutics?

Is EDIT or BEAM more profitable?

Do analysts rate EDIT or BEAM?

Do institutionals & insiders hold more shares of EDIT or BEAM?

Which has higher valuation & earnings, EDIT or BEAM?

Does the media favor EDIT or BEAM?

Which has more volatility and risk, EDIT or BEAM?

Summary

How does Editas Medicine compare to CRISPR Therapeutics?

Which has stronger valuation & earnings, CRSP or EDIT?

Do insiders & institutionals have more ownership in CRSP or EDIT?

Do analysts rate CRSP or EDIT?

Does the media prefer CRSP or EDIT?

Is CRSP or EDIT more profitable?

Which has more risk & volatility, CRSP or EDIT?

Summary

How does Editas Medicine compare to Intellia Therapeutics?

Do insiders and institutionals hold more shares of NTLA or EDIT?

Do analysts prefer NTLA or EDIT?

Which has better earnings and valuation, NTLA or EDIT?

Does the media refer more to NTLA or EDIT?

Is NTLA or EDIT more profitable?

Which has more risk & volatility, NTLA or EDIT?

Summary

How does Editas Medicine compare to Immatics?

Which has more volatility and risk, IMTX or EDIT?

Does the media prefer IMTX or EDIT?

Do analysts rate IMTX or EDIT?

Do insiders & institutionals believe in IMTX or EDIT?

Is IMTX or EDIT more profitable?

Which has preferable valuation & earnings, IMTX or EDIT?

Summary

How does Editas Medicine compare to Corvus Pharmaceuticals?

Do insiders and institutionals believe in CRVS or EDIT?

Which has more risk and volatility, CRVS or EDIT?

Is CRVS or EDIT more profitable?

Which has preferable earnings & valuation, CRVS or EDIT?

Do analysts prefer CRVS or EDIT?

Does the media prefer CRVS or EDIT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDIT vs. The Competition

Editas Medicine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools